rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

CNS Pharmaceuticals, Inc.

CNSP · Nasdaq

Health CareBiotechnologyIn trend

CNSP stood above a rising 150-day average in 5 of the last 52 weekly readings, including each of the last 5 weeks. It is 6.9% above that average now. Biotechnology: 16% of its 561 stocks in an uptrend (−15 points in four weeks); Health Care: 26% (−10 points in four weeks).

Statistics

Rotation
In trend
Weeks in an uptrend
5 in a row
Industry in uptrend
16% -15 in 4 wk
Insider buys, 12 months
$88K
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
11 (+0)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 5 of 52 weeks.

20 Apr – 19 Oct
17%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
$0$85KNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months2
Sale orders, 12 months0
Buyers · sellers2 · 0
WhoDidSharesTraded
Faith L. CharlesDirectorbought7,100at $4.7918 May 2026filed 20 May 2026
Michal FisherDirectorbought2,000at $5.0018 May 2026filed 18 Aug 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders11+0 on the quarter
New · exited4 · 4
Reported value$7.6M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
Stonepine Capital Management, LLCadded · filed 14 Aug 20261,345,921$6.4M+1,284,921+2106.4%
Ikarian Capital, LLCadded · filed 14 Aug 2026135,830$649K+90,000+196.4%
ADAR1 Capital Management, LLCnew · filed 14 Aug 202670,000$335K+70,000
BOOTHBAY FUND MANAGEMENT, LLCunchanged · filed 14 Aug 202613,524$65K00.0%
VANGUARD FIDUCIARY TRUST COnew · filed 13 Aug 202610,226$49K+10,226
VANGUARD CAPITAL MANAGEMENT LLCnew · filed 13 Aug 20266,993$33K+6,993
UBS Group AGadded · filed 13 Aug 20261,461$6,983+732+100.4%
Tower Research Capital LLC (TRC)reduced · filed 11 Aug 2026799$3,819-511−39.0%
BARCLAYS PLCnew · filed 14 Aug 202619$91+19
BARRETT & COMPANY, INC.unchanged · filed 24 Jul 20268$3800.0%
31 Mar 2024 – 30 Jun 2026
21221Mar 24Sep 24Jun 25Dec 25Jun 26

News

No headline names it lately.

Everyone who traded it

Rami Levin Company insiderCEO and President · last 14 Aug 20260 · 0
Faith L. Charles Company insiderDirector · last 18 May 20261 · 0
Michal Fisher Company insiderDirector · last 18 May 20261 · 0
Eric Faulkner Company insiderChief Technology Officer · last 2 Mar 20260 · 0
Steve O'Loughlin Company insiderChief Financial Officer · last 2 Mar 20260 · 0
Amy Mahery Company insiderDirector · last 17 Nov 20250 · 0
Bettina M. Cockroft Company insiderDirector · last 17 Nov 20250 · 0
Christopher Downs Company insiderChief Financial Officer · last 17 Nov 20256 · 0
Jeffry R. Keyes Company insiderDirector · last 17 Nov 20250 · 0
Jerzy Gumulka Company insiderDirector · last 17 Nov 20253 · 0
John M. Climaco Company insiderChief Executive Officer · last 17 Nov 20253 · 0
Carl Anthony Evans Company insiderDirector · last 8 Apr 20241 · 0

Same industry

MRNA ModernaLeading+154%
ENTX Entera BioLeading+49%
XNCR XencorLeading+32%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Share count trendFY 2025 · to 31 Mar 202628.3%
Cash and equivalentsFY 2025 · to 31 Dec 2025$7.2M
Free cash flowFY 2025 · to 31 Dec 2025−$13.8M

Analyst forecasts

No analyst forecasts yet.